Optometry Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Location status: Recruiting
NCT Number: NCT06948357
A multicenter, randomized, double-Blind, crossover, placebo-controlled Phase II clinical Study to evaluate the efficacy and safety of BRIMOCHOL PF and CARBACHOL PF in the treatment of Chinese patients with presbyopia.
Interested in participating?
Request Info45 year–75 year
All sexes
Interventional
Phase 2
Wenzhou, Zhejiang, China
Location status: Recruiting
119 subjects were planned to be enrolled in this study and randomly assigned in equal proportions into 7 treatment sequences. Each subject will receive a total of 7 treatments, each treatment period will be 1 day, and two adjacent visits during the treatment period need to be eluted for at least 3 days。
The study period included the screening period (Day 14~Day 1) with 1 visit and the treatment period (Day 0~Day 30) with 7 visits. There were a total of 8 visits in this study, with a duration of 32 to 45 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BRIMOCHOL PF eye drops, CARBACHOL PF eye drops, Brimonidine eye drops and Placebo were administered in 7 treatment sequences in various combinations and doses
Time frame: 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after administration
In the mesopic condition, the proportion of subjects whose MCNVA in the study eye increased by ≥15 ETDRS letters and whose MCDVA in the study eye did not decrease by ≥5 ETDRS letters from the pre-dose baseline at 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after dosing.
Time frame: 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after administration
Time frame: 15 minutes to 8 hours after administration
Mean ETDRS letter gain in study eye MCNVA compared to the baseline measurements under mesopic conditions across all post-dose evaluation intervals (15 minutes through 8 hours).
Time frame: 15 minutes to 8 hours after administration
The weighted mean of the area under the curve (AUC) for the increase in MCNVA ETDRS letter gain from baseline under mesopic conditions in the study eye across post-dose evaluation intervals (15 minutes through 8 hours).
Time frame: 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after administration
Time frame: 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after administration
Quantitative changes in pupil diameter (measured in study eye and binocular average) from pre-dose baseline values under mesopic conditions at 15minutes, 1hour, 2hour, 4hour15minutes, 6hour, and 8hour after administration.
Contact information is provided by the study sponsor or research team.
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Industry
A Multicenter, Randomized, Double-Blind, Crossover, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BRIMOCHOL PF, CARBACHOL PF in Chinese Patients With Presbyopia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07484191
Aphakia, Cataract
Campsie, New South Wales, Australia
View Trial DetailsNCT07512089
Eye Diseases, Presbyopia
Guangzhou, Guangdong, China
View Trial DetailsNCT07638943
Contact Lens Comfort and Successful Refitting, Eye Diseases
La Jolla, California, United States
View Trial DetailsNCT07637500
Eye Diseases, Presbyopia
Heidelberg, Germany
View Trial Details